Related Experiment Videos
Identification of an acidic ribosomal protein reactive with anti-Sm autoantibody
1Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.
Abstract:
Autoantibody to Sm Ag is a highly specific marker for the diagnosis of SLE. The Sm Ag exists in the cell nucleus as part of a ribonucleoprotein complex containing five small nuclear RNA. The major immunoreactive Sm species have been reported to be three polypeptides of m.w. 28,000/29,000 (B/B') and 16,000 (D). We report here that a m.w. 21,000 peptide is another major target of anti-Sm antibody. This peptide was originally identified by Western blotting as an acidic ribosomal protein (RP21) reactive with IgG from some SLE patients. Anti-RP21 is distinct from anti-ribosomal P protein antibody (anti-P) which has been previously identified as a lupus-specific autoantibody. Cell fractionation experiments showed that RP21 existed only in the ribosomal fraction and was never detected in other cellular compartments including nuclei. However, when nuclear extracts were used as Ag sources in immunoblotting, affinity-purified anti-RP21 was found to react with m.w. 28,000 and 16,000 peptides, suggesting that anti-RP21 reactivity might be due to the cross-reaction of anti-Sm. This was further confirmed by the evidence that two kinds of murine anti-Sm mAb independently derived from MRL/lpr mouse recognized RP21. These results indicate that anti-Sm antibodies in SLE are reactive with both nuclear and ribosomal ribonucleoproteins. Previous reports have described certain similarities, i.e., antibody subclass restriction and incidence, of anti-Sm and anti-P in both humans and autoimmune mice. Our present study demonstrated a close physical association of target molecules reactive with anti-Sm and anti-P, and might, therefore, provide some clue to the origin of these two types of lupus-specific autoantibodies.
Insights
Autoantibodies against Sm antigen (Sm Ag) are key for diagnosing SLE. This study identifies a new target, ribosomal protein RP21, revealing anti-Sm antibodies react with both nuclear and ribosomal components.
Area of Science:
- Immunology
- Molecular Biology
- Rheumatology
Background:
- Anti-Sm autoantibodies are highly specific diagnostic markers for Systemic Lupus Erythematosus (SLE).
- Sm antigen is a nuclear ribonucleoprotein complex, with known reactive polypeptides B/B' and D.
- Previous research identified anti-ribosomal P protein (anti-P) as another lupus-specific autoantibody.
Purpose of the Study:
- To identify novel targets of anti-Sm antibodies in SLE patients.
- To investigate the relationship between anti-Sm and anti-ribosomal P protein (anti-P) autoantibodies.
Main Methods:
- Western blotting using SLE patient IgG to identify reactive peptides.
- Cell fractionation to determine the cellular localization of the identified peptide (RP21).
- Immunoblotting with affinity-purified anti-RP21 and murine anti-Sm monoclonal antibodies (mAbs).
Main Results:
- A 21,000 molecular weight peptide, identified as acidic ribosomal protein RP21, was found to be a major target of anti-Sm antibodies.
- RP21 was localized to the ribosomal fraction, not the nucleus.
- Anti-RP21 reactivity with nuclear extracts showed cross-reactivity with Sm antigen components (28,000 and 16,000 MW peptides), confirmed by murine anti-Sm mAbs recognizing RP21.
Conclusions:
- Anti-Sm antibodies in SLE patients target both nuclear ribonucleoproteins and ribosomal protein RP21.
- These findings suggest a potential cross-reactivity between anti-Sm and anti-P autoantibodies.
- The study provides insights into the origin and potential shared mechanisms of these lupus-specific autoantibodies.